Abstract
ObjectiveTo assess the risk of adverse events associated with heterologous primary (two dose) and booster (three dose) vaccine schedules for covid-19 with Oxford-AstraZeneca’s ChAdOx1-S priming followed by mRNA vaccines (Pfizer-BioNTech’s...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have